Immunocore Is the Latest to Nab a Private Placement, Securing $140M to Pursue More TCR R&D

Published on : Published by : BioBuzz Media

Look­ing to se­cure a fresh raise to in­vig­o­rate R&D, Im­muno­core is putting to­geth­er a PIPE.
The for­mer Medi­gene spin­out, six months af­ter the FDA ap­proved its TCR drug tebenta­fusp, put out word Mon­day that it’s sell­ing just over 3.7 mil­lion shares of com­pa­ny stock at $37.50 each. This is go­ing to cer­tain in­vestors as a PIPE fi­nanc­ing for a to­tal of $140 mil­lion.